《星岛》记者 秦亦 深圳报道 近期，创尔生物（NQ:831187）发布公告，宣布终止北交所上市辅导备案，意味着该公司推进三年之久 的IPO之路正式折戟，一场筹备已久的资本市场冲刺最终未能如愿。 ▲创尔生物终止上市辅导。 创尔生物主要产品为医疗器械类和生物护肤类，在医疗器械方面，该公司已掌握生物医用级活性胶原大 规模无菌提取制备技术，拥有2个Ⅲ类及2个Ⅱ类医疗器械注册证。2017-2019年，公司胶原类产品在我 国医药级胶原市场的市场份额分别为3.04%、3.40%和5.23%。 创尔生物并未在公告中披露股东股权冻结的细节，但据《星岛》了解，这与其二股东丁玉梅有直接关 联。根据创尔生物2025年半年报显示，丁玉梅持有该公司365.36万股，持股比例4.30%，成为第二大股 东。不过，这部分股权已悉数被司法冻结，无任何可流通空间。 事实上，创尔生物的上市之路并非一帆风顺，2020年该公司曾冲击科创板，2021年撤回上市申请材料后 转向北交所，如今却因一桩股权隐患再度停摆。 | | | | | | | | | 期末 | 单位:股 | | --- | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - Chuang'er Bio has officially terminated its IPO preparation after three years of efforts, marking a significant setback in its capital market ambitions [1]. Company Overview - Chuang'er Bio specializes in medical devices and bio-skincare products, having developed large-scale sterile extraction technology for bio-medical grade active collagen, with 2 Class III and 2 Class II medical device registrations [3]. - The company's market share in the pharmaceutical-grade collagen market in China was 3.04% in 2017, 3.40% in 2018, and 5.23% in 2019 [3]. IPO Journey - The company's IPO journey has faced challenges, including an attempt to list on the Sci-Tech Innovation Board in 2020, which was followed by a withdrawal of the application in 2021 and a shift to the Beijing Stock Exchange [4]. - In July 2023, Chuang'er Bio signed a listing guidance agreement with Guotou Securities and submitted the necessary materials to the Guangdong Securities Regulatory Bureau, but the process was halted due to unresolved shareholder equity freeze issues [4]. Shareholder Issues - The termination of the IPO guidance was influenced by a long-standing equity freeze involving the company's second-largest shareholder, Ding Yumei, who holds 365,360 shares (4.30% ownership) that are currently frozen [4][6]. - Ding Yumei's equity freeze is linked to her previous marriage to Xu Jiayin, the former chairman of the now-defunct Evergrande Group, and is part of a broader debt resolution process involving Evergrande [6][7]. Legal and Financial Context - In 2022, Ding Yumei was reported to have reached a "technical divorce" with Xu Jiayin, interpreted as a financial separation to avoid debt liabilities [7]. - Legal actions have been initiated to recover approximately $6 billion in dividends and compensation from Xu Jiayin, Ding Yumei, and other former executives of Evergrande, leading to global asset freezing orders against Ding Yumei [7].